{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:05:53Z","timestamp":1790805953285,"version":"4.1.0"},"reference-count":73,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T00:00:00Z","timestamp":1363910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Hypertriglyceridemia (HTG) is commonly encountered in lipid and cardiology clinics. Severe HTG warrants treatment because of the associated increased risk of acute pancreatitis. However, the need to treat, and the correct treatment approach for patients with mild to moderate HTG are issues for ongoing evaluation. In the past, it was felt that triglyceride does not directly contribute to development of atherosclerotic plaques. However, this view is evolving, especially for triglyceride-related fractions and variables measured in the non-fasting state. Our understanding of the etiology, genetics and classification of HTG states is also evolving. Previously, HTG was considered to be a dominant disorder associated with variation within a single gene. The old nomenclature includes the term \u201cfamilial\u201d in the names of several hyperlipoproteinemia (HLP) phenotypes that included HTG as part of their profile, including combined hyperlipidemia (HLP type 2B), dysbetalipoproteinemia (HLP type 3), simple HTG (HLP type 4) and mixed hyperlipidemia (HLP type 5). This old thinking has given way to the idea that genetic susceptibility to HTG results from cumulative effects of multiple genetic variants acting in concert. HTG most is often a \u201cpolygenic\u201d or \u201cmultigenic\u201d trait. However, a few rare autosomal recessive forms of severe HTG have been defined. Treatment depends on the overall clinical context, including severity of HTG, concomitant presence of other lipid disturbances, and the patient's global risk of cardiovascular disease. Therapeutic strategies include dietary counselling, lifestyle management, control of secondary factors, use of omega-3 preparations and selective use of pharmaceutical agents.<\/jats:p>","DOI":"10.3390\/nu5030981","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T12:44:31Z","timestamp":1363956271000},"page":"981-1001","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Hypertriglyceridemia"],"prefix":"10.3390","volume":"5","author":[{"given":"Amanda","family":"Brahm","sequence":"first","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5K8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hegele","sequence":"additional","affiliation":[{"name":"Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5K8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2013,3,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: Its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"Can. Med. Assoc. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrg2481","article-title":"Plasma lipoproteins: Genetic influences and clinical implications","volume":"10","author":"Hegele","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1194\/jlr.R009720","article-title":"Genetic determinants of plasma triglycerides","volume":"52","author":"Johansen","year":"2011","journal-title":"J. Lipid Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MOL.0b013e3283471972","article-title":"Genetic bases of hypertriglyceridemic phenotypes","volume":"22","author":"Johansen","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11883-012-0243-2","article-title":"The complex genetic basis of plasma triglycerides","volume":"14","author":"Johansen","year":"2012","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bbalip.2011.10.007","article-title":"Allelic and phenotypic spectrum of plasma triglycerides","volume":"1821","author":"Johansen","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"(2001). Executive Summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA, 285, 2486\u20132497.","DOI":"10.1001\/jama.285.19.2486"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: An endocrine society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1093\/hmg\/ddp361","article-title":"A polygenic basis for four classical Frederickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia","volume":"18","author":"Hegele","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0022-3476(98)70280-X","article-title":"Familial lipoprotein lipase deficiency in infancy: Clinical, biochemical, and molecular study","volume":"133","author":"Godard","year":"1998","journal-title":"J. Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ymgme.2007.10.007","article-title":"Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum","volume":"93","author":"Rahalkar","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_12","first-page":"15","article-title":"The best diagnosis is: Eruptive xanthoma","volume":"90","author":"Hall","year":"2012","journal-title":"Cutis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.10702","article-title":"Research committee for primary hyperlipidemia, research on measures against intractable diseases by the ministry of health, labour and welfare in Japan. Diagnosis and management of type I and type V hyperlipoproteinemia","volume":"19","author":"Gotoda","year":"2012","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1210\/jc.2005-1098","article-title":"Long-term course of lipoprotein lipase (LPL) deficiency due to homozygous LPL (Arita) in a patient with recurrent pancreatitis, retained glucose tolerance, and atherosclerosis","volume":"90","author":"Kawashiri","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1476-511X-10-157","article-title":"Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: A retrospective cohort study","volume":"10","author":"Sandhu","year":"2011","journal-title":"Lipids Health Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/011542650401900105","article-title":"The pathophysiology of pancreatitis","volume":"19","author":"Khokhar","year":"2004","journal-title":"Nutr. Clin. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/ATVBAHA.111.226100","article-title":"Triglycerides and heart disease: Still a hypothesis?","volume":"31","author":"Goldberg","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199609193351203","article-title":"Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene","volume":"335","author":"Benlian","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.ATV.2.1.44","article-title":"Triglyceride and cholesterol metabolism in primary hypertriglyceridemia","volume":"2","author":"Beil","year":"1982","journal-title":"Arteriosclerosis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1139\/Y09-005","article-title":"Novel LPL mutations associated with lipoprotein lipase deficiency: Two case reports and a literature review","volume":"87","author":"Rahalkar","year":"2009","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1073\/pnas.84.1.270","article-title":"Structure of apolipoprotein C-IIToronto, a nonfunctional human apolipoprotein","volume":"84","author":"Connelly","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/01.mol.0000217892.00618.54","article-title":"APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency","volume":"17","author":"Calandra","year":"2006","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1194\/jlr.R018689","article-title":"GPIHBP1, an endothelial cell transporter for lipoprotein lipase","volume":"52","author":"Young","year":"2011","journal-title":"J. Lipid Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.bbalip.2011.10.006","article-title":"Lipase maturation factor 1: A lipase chaperone involved in lipid metabolism","volume":"1821","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature09270","article-title":"Biological, clinical and population relevance of 95 loci for blood lipids","volume":"466","author":"Teslovich","year":"2010","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1161\/ATVBAHA.111.226365","article-title":"An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia","volume":"31","author":"Johansen","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/ng.628","article-title":"Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia","volume":"42","author":"Johansen","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1161\/CIRCGENETICS.111.960864","article-title":"Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia","volume":"5","author":"Johansen","year":"2012","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1567-5688(09)71810-0","article-title":"Severe hypertriglyceridemia: An indication for apheresis?","volume":"10","author":"Ewald","year":"2009","journal-title":"Atheroscler. Suppl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosissup.2010.03.004","article-title":"Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency","volume":"11","author":"Gaudet","year":"2010","journal-title":"Atheroscler. Suppl."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1161\/ATVBAHA.108.175620","article-title":"Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients","volume":"28","author":"Stroes","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/erc.11.53","article-title":"The relative importance of common and rare genetic variants in the development of hypertriglyceridemia","volume":"9","author":"Evans","year":"2011","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0022-2275(20)32417-2","article-title":"Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia) questions, quandaries, and paradoxes","volume":"40","author":"Mahley","year":"1999","journal-title":"J. Lipid Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s12098-008-0219-y","article-title":"Familial hypertriglyceridemia","volume":"75","author":"Tullu","year":"2008","journal-title":"Indian J. Pediatr."},{"key":"ref_35","unstructured":"Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D. (2001). Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill. [8th]."},{"key":"ref_36","unstructured":"Davignon, J., and Dufour, R. (2007). Primary Hyperlipidemias: An Atlas of Investigation and Diagnosis, Clinical Publishing."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2012.15","article-title":"The genetics of familial combined hyperlipidaemia","volume":"8","author":"Brouwers","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0140-6736(74)92653-1","article-title":"Correction of essential fatty-acid deficiency in man by the cutaneous application of sunflower-seed oil","volume":"303","author":"Press","year":"1974","journal-title":"Lancet"},{"key":"ref_39","unstructured":"Larsen, P.R., Kronenberg, H.M., Melmed, S., and Polonsky, K.S. (2003). Williams Textbook of Endocrinology, Elsevier Science. [10th]."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1001\/jama.1989.03430220077034","article-title":"The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study","volume":"262","author":"Leaf","year":"1989","journal-title":"JAMA"},{"key":"ref_42","first-page":"69","article-title":"Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: A double-blind, placebo-controlled multicenter US study","volume":"11","author":"Goldberg","year":"1989","journal-title":"Clin. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0021-9150(89)90221-9","article-title":"Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III","volume":"78","author":"Bard","year":"1989","journal-title":"Atherosclerosis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0031-6989(86)90167-0","article-title":"Long-term effect of fenofibrate on lipoprotein level and composition in different types of genetic hyperlipidemias","volume":"18","author":"Baggio","year":"1986","journal-title":"Pharmacol. Res. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0002-8703(99)70262-0","article-title":"Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia","volume":"138","author":"Civeira","year":"1999","journal-title":"Am. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1161\/01.CIR.0000057982.50167.6E","article-title":"Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: The diabetes atherosclerosis intervention study (DAIS)","volume":"107","author":"Vakkilainen","year":"2003","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0002-9343(87)90871-0","article-title":"Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia","volume":"83","author":"Knopp","year":"1987","journal-title":"Am. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group","volume":"341","author":"Rubins","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"(2000). Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The bezafibrate infarction prevention (BIP) study. Circulation, 102, 21\u201327.","DOI":"10.1161\/01.CIR.102.1.21"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"ACCORD Study Group, Ginsberg, H.N., Elam, M.B., Lovato, L.C., Crouse, J.R.,  Leiter, L.A., Linz, P., Friedewald, W.T., Buse, J.B., and Gerstein, H.C. (2010). Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med., 362, 1563\u20131574.","DOI":"10.1056\/NEJMoa1001282"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.amjmed.2009.03.030","article-title":"Effect of fibrates on lipid profiles and cardiovascular outcomes: A systematic review","volume":"122","author":"Abourbih","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_62","first-page":"1312","article-title":"Pleiotropic effects of HMG-CoA reductase inhibitors","volume":"3","author":"Bocan","year":"2002","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","article-title":"Drug treatment of lipid disorders","volume":"341","author":"Knopp","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.atherosclerosis.2006.11.028","article-title":"Effect of rosuvastatin 5\u201320 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia","volume":"194","author":"Saito","year":"2007","journal-title":"Atherosclerosis"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/BF00180314","article-title":"The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia","volume":"70","author":"Feussner","year":"1992","journal-title":"Clin. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0026-0495(90)90256-C","article-title":"The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia","volume":"39","author":"Illingworth","year":"1990","journal-title":"Metabolism"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin","volume":"95","author":"Jones","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jacc.2005.11.072","article-title":"Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia","volume":"47","author":"McKenney","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"27i","DOI":"10.1016\/j.amjcard.2005.12.024","article-title":"Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids","volume":"98","author":"Davidson","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1517\/14656566.9.7.1237","article-title":"Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia","volume":"9","author":"West","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/01.ATV.11.4.864","article-title":"Fish oil supplementation reduces beta-very low density lipoprotein in type III dysbetalipoproteinemia","volume":"11","author":"Dallongeville","year":"1991","journal-title":"Arterioscler. Thromb."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"(1999). Dietary supplementation with N-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo studio della sopravvivenza nell\u2019Infarto miocardico. Lancet, 354, 447\u2013455.","DOI":"10.1016\/S0140-6736(99)07072-5"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/5\/3\/981\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:45:43Z","timestamp":1760219143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/5\/3\/981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,22]]},"references-count":73,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,3]]}},"alternative-id":["nu5030981"],"URL":"https:\/\/doi.org\/10.3390\/nu5030981","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,22]]}}}